When bacteria cells replicate, they do so a little differently than human cells do. They don't undergo mitosis, a splitting that involves construction of spindles to carefully separate the DNA after ...
Partnership leverages Replicate's proprietary srRNA technology to create novel, scalable therapies for obesity, type 2 diabetes and other cardiometabolic diseases Replicate will receive research ...
California biotech Replicate Biosciences will receive up to $550 million from Novo Nordisk in an alliance that aims to track down new drugs for obesity and diabetes. The partners will develop new ...
Novo Nordisk has both internal research and external alliances pursuing new drugs that could shape the next generation of metabolic medicines. The pharmaceutical giant’s latest move is a partnership ...
When Miguel Ángel del Pozo got the email, he didn’t feel great about it. As the head of a lab at Madrid’s Centro Nacional de Investigaciones Cardiovasculares Carlos III, del Pozo had been lead author ...
Replicate Bioscience and Novo Nordisk collaborate to develop srRNA-based therapies for obesity, type 2 diabetes, and cardiometabolic diseases. Novo Nordisk receives an exclusive worldwide license to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results